Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
Sanofi
Tolebrutinib was generally well tolerated by all subjects across all study arms.
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
